Markers of response to CDK4 & 6 inhibition from neoMONARCH: A phase II neoadjuvant study of abemaciclib in postmenopausal women with hormone receptor positive, HER2 negative breast cancer

被引：1
|
作者：
Hurvitz, S.
Martin, M.
Wijayawardana, S.
Brahmachary, M.
Ebert, Pj
Young, S.
Jansen, V.
Slamon, D.
机构：
[1] Univ Calif Los Angeles, Los Angeles, CA USA
[2] Hosp Gen Univ Gregorio Maranon, Madrid, Spain
[3] Eli Lilly & Co, Indianapolis, IN 46285 USA
来源：
CANCER RESEARCH | 2019年 / 79卷 / 04期
关键词：
D O I：
10.1158/1538-7445.SABCS18-P3-10-08
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P3-10-08
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Clonal Evolution in Patients with Hormone Receptor Positive, HER-2 Negative Breast Cancer Treated with Chemotherapy or CDK4/6 Inhibitors
    Decker, Thomas
    Bichler, Matthias
    Birtel, Andrea
    Fischer, Gerhard
    Geiger, Kathrin
    Gaenger, Stella
    Nonnenbroich, Christoph
    Dechow, Tobias
    Muendlein, Axel
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (05) : 248 - 252
  • [22] Accessible model predicts response in hormone receptor positive HER2 negative breast cancer receiving neoadjuvant chemotherapy
    Mastrantoni, Luca
    Garufi, Giovanna
    Giordano, Giulia
    Maliziola, Noemi
    Di Monte, Elena
    Arcuri, Giorgia
    Frescura, Valentina
    Rotondi, Angelachiara
    Orlandi, Armando
    Carbognin, Luisa
    Palazzo, Antonella
    Miglietta, Federica
    Pontolillo, Letizia
    Fabi, Alessandra
    Gerratana, Lorenzo
    Pannunzio, Sergio
    Paris, Ida
    Pilotto, Sara
    Marazzi, Fabio
    Franco, Antonio
    Franceschini, Gianluca
    Dieci, Maria Vittoria
    Mazzeo, Roberta
    Puglisi, Fabio
    Guarneri, Valentina
    Milella, Michele
    Scambia, Giovanni
    Giannarelli, Diana
    Tortora, Giampaolo
    Bria, Emilio
    NPJ BREAST CANCER, 2025, 11 (01)
  • [23] Differential metabolic response of triple-negative and estrogen receptor-positive breast cancer cells to abemaciclib, a CDK4/6 inhibitor
    Jiang, Jun
    Bao, Xun
    Jiang, Yuanyuan
    Yue, Yang
    Huettemann, Maik
    Li, Jing
    CANCER RESEARCH, 2024, 84 (06)
  • [24] A phase 2 study of abemaciclib plus pembrolizumab for patients with hormone receptor positive (HR+), HER2 negative (HER2-) metastatic breast cancer (MBC)
    Rugo, H.
    Tolaney, S.
    Dickler, M.
    Kabos, P.
    Ho, C-L
    Wildiers, H.
    Jerusalem, G.
    Ales-Martinez, J. E.
    Hossain, A.
    Johnston, E.
    Gianni, L.
    CANCER RESEARCH, 2017, 77
  • [25] Risk Factors Incidence in Postmenopausal Women With Hormone Receptor Negative/HER2 Positive and Triple Negative Breast Cancer - Preliminary Results
    Lumachi, F.
    Basso, S. M. M.
    Marino, F.
    Orlando, R.
    Basso, U.
    Chiara, G. B.
    EUROPEAN JOURNAL OF CANCER, 2011, 47 : S251 - S251
  • [26] The Role of the CDK4/6 Inhibitor Ribociclib in Locally Advanced and Oligometastatic Hormone Receptor Positive, Her2 Negative, Advanced Breast Cancer: Case Series and Review of the Literature
    Botticelli, Andrea
    Fabbri, Agnese
    Roberto, Michela
    Alesini, Daniele
    Cirillo, Alessio
    D'Auria, Giuliana
    Krasniqi, Eriseld
    Marrucci, Eleonora
    Muratore, Margherita
    Pantano, Francesco
    Pizzuti, Laura
    Portarena, Ilaria
    Rossi, Rosalina
    Scagnoli, Simone
    Marchetti, Paolo
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [27] CDK4/6 Inhibitor Treatments in Patients with Hormone Receptor Positive, Her2 Negative Advanced Breast Cancer: Potential Molecular Mechanisms, Clinical Implications and Future Perspectives
    Roberto, Michela
    Astone, Antonio
    Botticelli, Andrea
    Carbognin, Luisa
    Cassano, Alessandra
    D'Auria, Giuliana
    Fabbri, Agnese
    Fabi, Alessandra
    Gamucci, Teresa
    Krasniqi, Eriseld
    Minelli, Mauro
    Orlandi, Armando
    Pantano, Francesco
    Paris, Ida
    Pizzuti, Laura
    Portarena, Ilaria
    Salesi, Nello
    Scagnoli, Simone
    Scavina, Paola
    Tonini, Giuseppe
    Vici, Patrizia
    Marchetti, Paolo
    CANCERS, 2021, 13 (02) : 1 - 20
  • [28] Dissecting the biological activity of different CDK4/6 inhibitors (CDK4/6i) in hormone receptor-positive/HER2-negative (HR+/HER2-) breast cancer (BC)
    Lorman-Carbo, Natalia
    Martinez-Saez, Olga
    Fernandez-Martinez, Aranzazu
    Galvan, Patricia
    Chic, Nuria
    Adamo, Barbara
    Vidal, Maria
    Munoz, Montserrat
    Perou, Charles M.
    Gavila, Joaquin
    Pascual, Tomas
    Prat, Aleix
    Braso-Maristany, Fara
    CANCER RESEARCH, 2023, 83 (05)
  • [29] Biomarker associated with response to CDK4/6 inhibitors in metastatic hormone receptor positive breast cancer
    Witkiewicz, Agnieszka
    CANCER RESEARCH, 2023, 83 (05)
  • [30] Hormone receptor-positive HER2-low metastatic breast cancer (mBC): evolution of HER2 status after CDK4/6 inhibitor treatment
    de Nonneville, Alexandre
    Finetti, Pascal
    Boudin, Laurys
    Usclade, Lucas
    Mescam, Lenaig
    Durieux, Emeline
    Boucraut, Agathe
    Viret, Frederic
    Mamessier, Emilie
    Goncalves, Anthony
    Bertucci, Francois
    CANCER RESEARCH, 2024, 84 (09)
12345